CD33 and acute myeloid leukemia: CD33 has been the target of multiple immunotherapy strategies that target AML in preclinical and clinical research [26], but only one CD33-targeted therapeutic has been FDA approved for pAML—gemtuzumab ozogamicin/MYLOTARG (GO).